Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH
Johannes Oldenburg, Robert Klamroth, Florian Länger, Manuela Albisetti, Charis von Auer, Cihan Ay, Wolfgang Korte, Rüdiger E. Scharf, Bernd Pötzsch, Andreas Greinacher
Abstract
The COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication. It shares pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
Topics & Concepts
MedicineVaccinationCoronavirus disease 2019 (COVID-19)ThrombosisPandemicComplication2019-20 coronavirus outbreakIntensive care medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyPediatricsInternal medicineVirologyDiseaseInfectious disease (medical specialty)OutbreakHeparin-Induced Thrombocytopenia and ThrombosisVenous Thromboembolism Diagnosis and ManagementIntramuscular injections and effects